We read with great interest the article by Dima et al. on the clinical significance of the anti-Nucleolar Organizer Region antibodies (NOR90) in systemic sclerosis (SSc) [1]. The authors conducted a cross-sectional retrospective study as part of European Scleroderma Trials and Research Group (EUSTAR), representing the largest cohort of SSc patients tested for NOR90. They confirmed that the prevalence of NOR90 in SSc patients is approximately 3 %, with the majority (32/44, 72.7 %) of NOR90-positive patients also testing positive for other SSc-criteria antibodies.
